Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 2

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
332,455,081)
  
    Accumulated other comprehensive income (loss) 
     775,611  
     (170,846)
  
    Total Stockholders’ Equity 
     88,386,851  
     131,977,144 

    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 
    $117,726,120  
    $163,129,450 

See accompanying notes to the unaudited condensed consolidated
financial statements.

2

RENOVARO INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

For the Three Months Ended
 
For the Nine Months Ended

March 31,
 
March 31,

2025
 
2024
 
2025
 
2024

Operating Expenses

General and administrative
 
$
4,224,590

$
7,652,379

$
13,878,963

$
19,558,981

Research and development

(94,073
)

1,087,156

457,200

2,274,321

Goodwill impairment

—

—

47,614,729

—

Intangible asset impairment

—

42,611,000

—

42,611,000

Depreciation and amortization

31,975

30,305

96,469

90,727

Total Operating Expenses

4,162,492

51,380,840

62,047,361

64,535,029

LOSS FROM OPERATIONS

(4,162,492
)

(51,380,840
)

(62,047,361
)

(64,535,029
)

Other Income (Expenses)

Change in fair value of contingent consideration

4,330,000

(7,289,156
)

10,990,000

(7,289,156
)

Change in fair value of equity securities

210,281

—

210,281

—

Loss on extinguishment of debt

—

—

—

(120,018
)

Interest expense

(188,685
)

(303,802
)

(537,656
)

(758,057
)

Interest and other income

72

(16,272
)

109,483

8,041

Total Other Income (Expense)

4,351,668

(7,609,230
)

10,772,108

(8,159,190